Product Images Donepezil Hydrochloride

Donepezil Hydrochloride Tablets, USP is a prescription medication used for the treatment of mild to moderate dementia caused by Alzheimer's disease. This medication comes in a pack of 100 tablets with each tablet containing 10mg of the active ingredient. The dosage should be determined by a healthcare professional. The manufacturer of Donepezil Hydrochloride Tablets is Gmaior.*

This is a description of a medication that contains Donepezil Hydrochloride in the form of Unit Dose Tablets. The medication is labeled with an NDC code and comes in a bottle containing 100 tablets. The pharmacist should dispense it with a patient information sheet. The rest of the text appears to be illegible due to errors.*

This is a table showing the change from baseline in ADAS-cog over the course of 18 weeks of drug treatment. The table includes data for Donepezil Hydrochloride Tablets at 5mg/day and 10mg/day and for placebo. The data is divided into Clinical Improvement and Clinical Decline categories. The table also includes the weeks of treatment on the x-axis.*

Cumulative percentage of patients experiencing improvement or no change in ADAS-cog scores over time for donepezil hydrochloride tablets (5mg/day and 10mg/day) compared to a placebo group. The graph shows that a higher percentage of patients treated with donepezil hydrochloride tablets had improvements in cognitive function compared to those who received a placebo.*

This is a chart depicting the percentage of patients who experienced improvement or worsening in their CIBIC-plus rating after taking either BN Donepezil Hydrochloride Tablets at either 10 mg/day or 5 mg/day or a placebo. The chart also includes a scale for determining the level of improvement, with options ranging from "Markedly Improved" to "Markedly Worse."*

This appears to be a graph showing the ADAS-cog change from baseline for three different groups - one group taking Donepezil hydrochloride tablets 10mg/day, one group taking Donepezil hydrochloride tablets 5mg/day, and a placebo group. There are four time points labeled on the x-axis - 0, 3, 6, and 9 weeks of drug treatment. The y-axis shows the ADAS-cog change from baseline, with mean values and standard errors depicted. The graph also includes labels for "Clinical Improvement" and "Clinical Decline".*

This is a chart displaying the cumulative percentage of patients who experienced different levels of change in ADAS-COG (Alzheimer's Disease Assessment Scale-Cognitive Subscale) score from baseline after being treated with Donepezil Hydrochloride Tablets at either 5mg/day or 10mg/day. The chart shows that a higher percentage of patients who received treatment with Donepezil Hydrochloride Tablets at 5mg/day and 10mg/day experienced a decrease in ADAS-COG score compared to patients who received a placebo. The chart also displays the percentage of patients who experienced no change in ADAS-COG score.*

This is a figure showing the time course of change of ADCS-ADL-Severe score for patients who completed 6 months of treatment. It compares the clinical improvement and decline of patients using donepezil hydrochloride tablets 10mg/day and placebo. The x-axis shows the months of drug treatment while the y-axis represents the score.*

The text provides a graph that shows the cumulative percentage of patients for Donepezil Hydrochloride Tablets 10 mg/day and Placebo. The graph also shows the change from baseline on the ADCS-ADL scale. It appears to be a comparison study on the efficacy of Donepezil Hydrochloride Tablets.*